Answers are grounded in this paper and cite their sources.
Cohort study finds worse survival outcomes in inflammatory breast cancer, suggesting treatment gaps.
In this cohort study of stage III BC, IBC was associated with worse BCSS and OS than stage III non-IBC across all tumor subtypes. TMT use in IBC was low and decreased significantly over time. BCSS and OS did not improve over time for patients with IBC treated with TMT, whereas BCSS and OS improved for those with non-IBC.
No takes yet. Share an insight, caveat, or question.
Leone et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: